BIOMAT Database Logo BIOMAT Database Logo

Rate of thymidine analogue resistance mutation accumulation with zidovudine- or stavudine-based regimens. 2004

Daniel R Kuritzkes, and Roland L Bassett, and J Darren Hazelwood, and Heidi Barrett, and Ruth A Rhodes, and Russell K Young, and Victoria A Johnson, and
University of Colorado Health Sciences Center, Denver, CO, USA. dkuritzkes@partners.org

Zidovudine (ZDV) and stavudine (d4T) select for the same set of thymidine analogue resistance mutations (TAMs). To compare the rate at which TAMs emerge, genotypic analysis of HIV-1 was performed on serial plasma samples from treatment-naive subjects randomly assigned to receive ZDV or d4T in combination with lamivudine. After 72 weeks of follow-up, TAMs were detected in samples from 50% of ZDV-treated subjects and 45% of d4T-treated subjects (P = 0.79). The frequency of K70R and T215Y or F mutations was similar in both groups, although M41L was observed more frequently in samples from ZDV-treated subjects. This randomized study shows that TAMs accumulate at similar rates during treatment with ZDV or d4T, but the specific pattern of mutations may differ somewhat in patients treated with these thymidine analogues.

UI MeSH Term Description Entries
D008969 Molecular Sequence Data Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories. Sequence Data, Molecular,Molecular Sequencing Data,Data, Molecular Sequence,Data, Molecular Sequencing,Sequencing Data, Molecular
D009154 Mutation Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations. Mutations
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D015215 Zidovudine A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia. AZT (Antiviral),Azidothymidine,3'-Azido-2',3'-Dideoxythymidine,3'-Azido-3'-deoxythymidine,AZT Antiviral,AZT, Antiviral,BW A509U,BWA-509U,Retrovir,3' Azido 2',3' Dideoxythymidine,3' Azido 3' deoxythymidine,Antiviral AZT,BWA 509U,BWA509U
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human
D018119 Stavudine A dideoxynucleoside analog that inhibits reverse transcriptase and has in vitro activity against HIV. 2',3'-Didehydro-3'-deoxythymidine,D4T,2',3'-Didehydro-2',3'-dideoxythmidine,BMY-27857,Stavudine, Monosodium Salt,Zerit,2',3' Didehydro 3' deoxythymidine,BMY 27857,BMY27857
D018894 Reverse Transcriptase Inhibitors Inhibitors of reverse transcriptase (RNA-DIRECTED DNA POLYMERASE), an enzyme that synthesizes DNA on an RNA template. Reverse Transcriptase Inhibitor,Inhibitors, Reverse Transcriptase,Inhibitor, Reverse Transcriptase,Transcriptase Inhibitor, Reverse
D019259 Lamivudine A reverse transcriptase inhibitor and ZALCITABINE analog in which a sulfur atom replaces the 3' carbon of the pentose ring. It is used to treat HIV disease. 2',3'-Dideoxy-3'-thiacytidine,2(1H)-Pyrimidinone, 4-amino-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-, (2R-cis)-,3TC Lamivudine,Lamivudine, (+)-cis-,Lamivudine, (+-)-trans-,BCH-189,Epivir,GR-109714X,GR109714X,Lamivudine, (2S-cis)-Isomer,2',3' Dideoxy 3' thiacytidine,BCH 189,BCH189,GR 109714X,Lamivudine, 3TC
D024921 Drug Resistance, Multiple, Viral The ability of viruses to resist or to become tolerant to several structurally and functionally distinct drugs simultaneously. This resistance phenotype may be attributed to multiple gene mutation. Drug Resistance, Extensive, Viral,Drug Resistance, Extensively, Viral,Extensive Antiviral Drug Resistance,Extensively Antiviral Drug Resistance,Multidrug Resistance, Viral,Multiple Antiviral Drug Resistance,Resistance, Viral Multidrug,Viral Multidrug Resistance,Viral Multidrug Resistances

Related Publications

Daniel R Kuritzkes, and Roland L Bassett, and J Darren Hazelwood, and Heidi Barrett, and Ruth A Rhodes, and Russell K Young, and Victoria A Johnson, and
Rate of accumulation of thymidine analogue mutations in patients continuing to receive virologically failing regimens containing zidovudine or stavudine: implications for antiretroviral therapy programs in resource-limited settings.
September 2009, The Journal of infectious diseases,
Daniel R Kuritzkes, and Roland L Bassett, and J Darren Hazelwood, and Heidi Barrett, and Ruth A Rhodes, and Russell K Young, and Victoria A Johnson, and
M184V is associated with a low incidence of thymidine analogue mutations and low phenotypic resistance to zidovudine and stavudine.
August 2002, AIDS (London, England),
Daniel R Kuritzkes, and Roland L Bassett, and J Darren Hazelwood, and Heidi Barrett, and Ruth A Rhodes, and Russell K Young, and Victoria A Johnson, and
Thymidine analogue mutations in antiretroviral-naive HIV-1 patients on triple therapy including either zidovudine or stavudine.
January 2004, The Journal of antimicrobial chemotherapy,
Daniel R Kuritzkes, and Roland L Bassett, and J Darren Hazelwood, and Heidi Barrett, and Ruth A Rhodes, and Russell K Young, and Victoria A Johnson, and
Thymidine-analog and multi-nucleoside resistance mutations are observed in both zidovudine-naive and zidovudine-experienced subjects with viremia after treatment with stavudine-containing regimens.
January 2001, Journal of human virology,
Daniel R Kuritzkes, and Roland L Bassett, and J Darren Hazelwood, and Heidi Barrett, and Ruth A Rhodes, and Russell K Young, and Victoria A Johnson, and
Thymidine analog and multinucleoside resistance mutations are associated with decreased phenotypic susceptibility to stavudine in HIV type 1 isolated from zidovudine-naive patients experiencing viremia on stavudine-containing regimens.
August 2001, AIDS research and human retroviruses,
Daniel R Kuritzkes, and Roland L Bassett, and J Darren Hazelwood, and Heidi Barrett, and Ruth A Rhodes, and Russell K Young, and Victoria A Johnson, and
Effect of zidovudine resistance mutations on virologic response to treatment with zidovudine or stavudine, each in combination with lamivudine and indinavir.
December 2002, Journal of acquired immune deficiency syndromes (1999),
Daniel R Kuritzkes, and Roland L Bassett, and J Darren Hazelwood, and Heidi Barrett, and Ruth A Rhodes, and Russell K Young, and Victoria A Johnson, and
Tolerability and effectiveness of first-line regimens combining nevirapine and lamivudine plus zidovudine or stavudine in Cameroon.
March 2008, AIDS research and human retroviruses,
Daniel R Kuritzkes, and Roland L Bassett, and J Darren Hazelwood, and Heidi Barrett, and Ruth A Rhodes, and Russell K Young, and Victoria A Johnson, and
Phenotypic resistance pattern of HIV-1 isolates with zidovudine and/or multidrug resistance mutations after didanosine-stavudine combination therapy.
December 2000, Journal of acquired immune deficiency syndromes (1999),
Daniel R Kuritzkes, and Roland L Bassett, and J Darren Hazelwood, and Heidi Barrett, and Ruth A Rhodes, and Russell K Young, and Victoria A Johnson, and
Increased incidence of symptomatic peripheral neuropathy among adults receiving stavudine- versus zidovudine-based antiretroviral regimens in Kenya.
June 2012, Journal of neurovirology,
Daniel R Kuritzkes, and Roland L Bassett, and J Darren Hazelwood, and Heidi Barrett, and Ruth A Rhodes, and Russell K Young, and Victoria A Johnson, and
Emergence of zidovudine resistance in HIV-infected patients receiving stavudine.
March 2000, Journal of acquired immune deficiency syndromes (1999),
Copied contents to your clipboard!